Monopar Therapeutics financial data

Symbol
MNPR on Nasdaq
Industry
Pharmaceutical Preparations
Location
1000 Skokie Blvd Suite 350, Wilmette, IL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -44.5%
Debt-to-equity 12.1 % -61.6%
Return On Equity -84.8 % +26.9%
Return On Assets -75.6 % +14.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.11M shares -65%
Common Stock, Shares, Outstanding 6.1M shares +105%
Entity Public Float 6.41M USD +39.2%
Common Stock, Value, Issued 6.1K USD +105%
Weighted Average Number of Shares Outstanding, Basic 3.79M shares +37.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13M USD +132%
General and Administrative Expense 3.16M USD -2.33%
Operating Income (Loss) -16.2M USD -83%
Net Income (Loss) Attributable to Parent -15.6M USD -85.5%
Earnings Per Share, Basic -4.11 USD/shares -35.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.8M USD +531%
Cash, Cash Equivalents, and Short-term Investments 10.4M USD
Other Assets, Current 78.9K USD +18.7%
Assets, Current 60.3M USD +722%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 60.3M USD +721%
Liabilities, Current 1.76M USD -43.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 5.25M USD +199%
Accumulated Other Comprehensive Income (Loss), Net of Tax 36K USD
Retained Earnings (Accumulated Deficit) -75.8M USD -25.9%
Stockholders' Equity Attributable to Parent 55M USD +885%
Liabilities and Equity 60.3M USD +721%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.66M USD +27.1%
Net Cash Provided by (Used in) Financing Activities 3.18M USD +295%
Net Cash Provided by (Used in) Investing Activities -983K USD +0.01%
Common Stock, Shares Authorized 40M shares 0%
Common Stock, Shares, Issued 6.1M shares +105%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 541K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.73M USD -67.9%
Deferred Tax Assets, Valuation Allowance 17.9M USD +34.7%
Deferred Tax Assets, Gross 17.9M USD +34.7%
Operating Lease, Liability 8.41K USD -85.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.5M USD -84.4%
Lessee, Operating Lease, Liability, to be Paid 8.48K USD -85.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.48K USD -83.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 68 USD -97.1%
Deferred Tax Assets, Operating Loss Carryforwards 4.48M USD +15.6%
Unrecognized Tax Benefits 412K USD +22.6%
Additional Paid in Capital 63.1M USD +4.01%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 476K USD -4.72%